# BioMarin Pharmaceutical Inc

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/BioMarin Pharmaceutical Inc).

## Overview

BioMarin Pharmaceutical Inc. is a San Rafael, California-based biotechnology company founded in 1997 that focuses on medicines for genetically defined rare diseases. Its business is built around eight commercial therapies, including VOXZOGO, VIMIZIM, NAGLAZYME, PALYNZIQ, ALDURAZYME, BRINEURA, KUVAN and ROCTAVIAN, plus a pipeline of clinical and preclinical programs. The company develops and commercializes category-defining treatments for serious and life-threatening conditions where patient populations are small but medically urgent. BioMarin sells directly in the U.S. and major international markets, while also using distributors and partners in selected countries. Its model combines internal R&D, targeted acquisitions and partnerships to expand its rare-disease portfolio over time.

## Products & services

• VOXZOGO for achondroplasia and skeletal conditions
• Enzyme therapies: VIMIZIM, NAGLAZYME, PALYNZIQ
• ALDURAZYME commercialized globally with Sanofi
• BRINEURA for CLN2 disease
• KUVAN for phenylketonuria
• ROCTAVIAN gene therapy for hemophilia A
• Pipeline programs including BMN 333 and BMN 401

- **Skeletal conditions** (29%) — Therapies for genetically defined skeletal disorders, centered on VOXZOGO.
- **Enzyme therapies** (63%) — Enzyme replacement and related therapies for ultra-rare metabolic and lysosomal diseases.
- **Gene therapy** (1%) — One-time or durable genetic medicines such as ROCTAVIAN for hemophilia A.
- **Legacy and other products** (7%) — Older products including KUVAN and smaller revenue streams from other commercialized assets.

- VOXZOGO for achondroplasia and skeletal conditions
- Enzyme therapies: VIMIZIM, NAGLAZYME, PALYNZIQ
- ALDURAZYME commercialized globally with Sanofi
- BRINEURA for CLN2 disease
- KUVAN for phenylketonuria
- ROCTAVIAN gene therapy for hemophilia A
- Pipeline programs including BMN 333 and BMN 401

## Customers

BioMarin sells primarily to specialty pharmacies, hospitals, government purchasers and authorized distributors that serve patients with rare genetic diseases. In the U.S., most products are sold through specialty pharmacies or end users such as hospitals, while PALYNZIQ is distributed through certified specialty pharmacies under a REMS program. Outside the U.S., the company often sells to distributors or directly to government purchasers and hospitals, which matters because large periodic government orders can create quarter-to-quarter volatility. Sanofi is the sole customer for ALDURAZYME and handles global distribution, marketing and sales of that product. The end demand ultimately comes from patients and treating specialists in rare-disease centers, so access, reimbursement and regulatory compliance are central to purchasing decisions.

- **U.S. specialty pharmacies** (primary) — Buy VOXZOGO, PALYNZIQ and other products for dispensing to patients, because access and reimbursement are managed through specialty channels.
- **Hospitals and treatment centers** (primary) — Purchase infused or administered therapies for rare-disease patients, especially in the U.S. and Europe.
- **Government purchasers and public health systems** (primary) — Place periodic large orders in certain countries, which drives international volume but also creates timing volatility.
- **Authorized distributors** (secondary) — Buy products for selected non-U.S. markets and handle local regulatory and commercial execution.
- **Sanofi** (primary) — Sole customer for ALDURAZYME, purchasing and commercializing the product globally.

- Specialty pharmacies that dispense rare-disease medicines in the U.S.
- Hospitals and treatment centers that administer infused therapies
- Government purchasers in countries with periodic bulk ordering
- Authorized distributors that resell in selected international markets
- Sanofi as the sole customer for ALDURAZYME
- Certified specialty pharmacies for PALYNZIQ under REMS
- End users and physicians treating genetically defined rare diseases

## Geography

BioMarin is headquartered in the United States and sells directly through commercial teams in the U.S., Europe, South America and other significant markets. The company also uses distributors in selected countries, especially outside the U.S., where regulatory approvals and named-patient sales can be handled locally. Its revenue base is global, but the business is exposed to regional ordering patterns, including large government purchases in parts of Latin America and the Middle East. The reports specifically note growth in VOXZOGO across all regions, PALYNZIQ primarily in the U.S., and ROCTAVIAN in the U.S. and Europe. Because the company operates across multiple currencies and healthcare systems, foreign exchange, reimbursement and trade conditions can affect both demand and timing of revenue recognition.

- United States is the core commercial market and headquarters location
- Europe is a major direct-sales region for VOXZOGO and ROCTAVIAN
- South America contributes through direct sales and distributor channels
- Middle East and Latin America can drive large government orders
- Selected markets are served by local distributors rather than BioMarin directly
- International sales timing can be uneven because of public-sector ordering
- Global operations create foreign exchange and regulatory exposure

## Strategy

BioMarin is focused on expanding its rare-disease franchise while selectively advancing or discontinuing R&D programs based on scientific merit and commercial potential. The company is prioritizing growth in VOXZOGO and its enzyme therapies, while also investing in next-generation assets such as BMN 333 and BMN 401 to deepen the pipeline. In July 2025 it completed the acquisition of Inozyme Pharma to strengthen the enzyme therapies portfolio, showing a willingness to use M&A to add late-stage assets. Management also highlighted cost transformation and updates to the commercial organization, which should support operating leverage as the product base grows. The strategy is to combine internal discovery, partnerships and acquisitions to build durable positions in rare diseases where specialized commercialization capabilities matter.

- **Expand VOXZOGO globally** (short-term) — VOXZOGO is a major growth driver and broadening patient initiation supports recurring rare-disease revenue.
- **Strengthen the enzyme therapies portfolio** (medium-term) — Enzyme replacement therapies remain the core cash-generating franchise and provide diversification across ultra-rare diseases.
- **Advance pipeline and portfolio discipline** (medium-term) — Rare-disease biotech depends on a steady flow of differentiated assets, but capital must be focused on programs with the best commercial odds.
- **Optimize commercialization and cost structure** (short-term) — A focused sales organization and cost transformation can improve efficiency while supporting launches and international expansion.

- Grow VOXZOGO and broaden its patient base across regions
- Expand enzyme therapies through organic R&D and acquisitions
- Advance late-stage pipeline assets such as BMN 401
- Use portfolio review to stop programs with weak commercial prospects
- Maintain a targeted commercial footprint in specialty rare-disease markets
- Pursue partnerships and external assets to supplement internal research
- Improve cost structure through commercial and organizational changes

## Risks

BioMarin faces the typical risks of a rare-disease biotech company: dependence on a small number of products, regulatory and clinical development uncertainty, and heavy reliance on specialized manufacturing and distribution. The company specifically notes that large periodic government orders can cause significant quarter-to-quarter revenue swings, and that generic competition has already reduced KUVAN sales after loss of exclusivity. Its ALDURAZYME business depends on Sanofi, so any disruption to that manufacturing, marketing and sales agreement would materially affect the product. Supply chain interruptions, raw material inflation, tariffs, geopolitical instability and foreign exchange volatility can also affect global operations because the company sells and manufactures across multiple regions. As with other biopharma companies, patent disputes, reimbursement changes, adverse clinical data, cybersecurity incidents and regulatory actions could all pressure revenue, margins and pipeline value.

- **Dependence on a limited number of commercial products** [high] — A large share of revenue comes from a small set of rare-disease therapies, so any slowdown in one product can materially affect results.
- **Large periodic government orders create revenue timing volatility** [medium] — Certain countries place bulk orders inconsistently, which can shift revenue between quarters and complicate forecasting.
- **Generic competition and loss of exclusivity** [high] — KUVAN has already been pressured by generic competition, showing the vulnerability of mature products after exclusivity ends.
- **Manufacturing and supply chain disruption** [high] — Biologic and enzyme therapies require reliable third-party logistics, raw materials and finished-product supply to meet demand and support trials.
- **Regulatory and clinical development risk** [high] — Pipeline value depends on successful trials and approvals, and setbacks can eliminate expected future revenue.
- **Counterparty dependence on Sanofi** [high] — ALDURAZYME is sold globally by Sanofi, so termination or disruption of that agreement would impair commercialization.

- Revenue concentration in a small number of products and customers
- Quarterly volatility from timing of large government orders
- Generic competition for KUVAN after loss of exclusivity
- Dependence on Sanofi for ALDURAZYME commercialization
- Manufacturing and supply interruptions for biologic products
- Clinical and regulatory failure risk for pipeline assets
- Foreign exchange, tariffs and geopolitical instability affecting global sales

## Accounting

BioMarin’s most important accounting judgments are tied to revenue recognition for specialty pharmaceuticals, especially products sold through distributors, hospitals and government purchasers. The company recognizes revenue when control transfers, but ALDURAZYME is more complex because BioMarin records variable consideration based on estimated payments from Sanofi and true-ups depend on actual sell-through. This makes revenue sensitive to estimates, order timing and channel mix, particularly when large government orders shift between quarters. The company also notes that its critical accounting estimates have not changed materially, but investors should still watch for allowance assumptions, returns, rebates and other deductions that can affect net product revenue. As a biotech company with acquisitions and a pipeline, BioMarin also faces judgment around asset acquisition accounting, intangible assets and potential impairment if programs are discontinued or underperform.

- **Revenue recognition and variable consideration** — Net revenue and quarterly comparability
- **ALDURAZYME sell-through accounting** — Revenue timing and estimate true-ups
- **Government order timing and seasonality** — Quarterly revenue volatility
- **Acquisition and asset accounting** — Balance sheet and expense recognition
- **Impairment and program discontinuation judgments** — R&D expense and asset values

- Revenue recognition at point of control transfer for most products
- ALDURAZYME variable consideration based on Sanofi sell-through
- Quarterly revenue swings from timing of large government orders
- Net product revenue affected by allowances, rebates and returns
- Acquisition accounting for Inozyme and other external assets
- Potential impairment risk for discontinued or underperforming programs

---

*Last updated: 2026-08-11T04:46:22.667099+00:00*